MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
← catalyst calendarNCT06128629 · readout ≤ 499 d
Sponsored by Intellia Therapeutics (industry) · NTLA — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,200estimated
Sites
132
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-13 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
- Biological: NTLA-2001
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFComposite outcome of cardiovascular (CV) mortality and CV events
measured Maximum study duration is dependent on event rates and is estimated to be at least 18 months and up to approximately 5 years
Permalink · NTLA's whole pipeline · Catalyst calendar · Every registered study · What changed